Global Leukemia Antibodies Market, Drug Sales & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Leukemia Cancer Antibodies Market, Drug Sales and Clinical Trials Insight 2028 Report Highlights:
The genomic analysis has demonstrated high expression of CD20 and CD33 on the leukemic cells. Therefore, these receptors have emerged as promising druggable targets for the immunotherapeutic approaches. At present, a cocktail of monoclonal antibodies and antibody drug conjugates directed towards these receptors have entered the global market. Moreover, bispecific antibody targeting CD19 as well as CD3 has also been approved for the management of acute lymphoblastic leukemia. The encouraging response of this therapeutics has propelled the further research and development activities in this domain. Presently, more than 100 clinical trials are ongoing in global leukemia antibody therapeutics market.
US is currently holding the maximum number of clinical trials in the market which is mainly attributed to the presence of major key players in the region associated with their huge investments in this segment. For instance, Immunogen has developed IMGN632, which is a CD123 targeted antibody drug conjugate in clinical development for the management of acute myeloid leukemia. Researchers are evaluating the role of investigational drug in combination with Vidaza (azacitidine) and Venclexta® (venetoclax) (triplet) in patients with relapsed/ refractory (R/R) acute myeloid leukemia. The drug is present in initial stages of development and is expected to gain entry in market during the forecast period.
Apart from US, China is also making huge investments in antibody therapeutics to cope up with the market growth. The China pharmaceutical market is also expanding at large rates owing to presence of both domestic as well as international players. The growth is reliant on supportive government policies, favorable healthcare coverage rates, advancements in medical technology, and new product launches in the market. In 2020, National Medical Products Administration (NMPA) of China has announced the approval of Halpryza (rituximab injection). In addition, other key growth drivers for the market in China include the ageing trend of Chinese population, rising healthcare expenditure, and improving the public medical insurance system.
At present, therapeutic monoclonal antibodies are currently dominating the global market which is mainly attributed to large number of product approved, availability of cost effective biosimilars, and favorable reimbursement policies. However, it is estimated that bispecific antibodies will emerge as potential therapeutic option in the management of leukemia owing to their enhanced efficacy and specificity in the management of disease. Although only one bispecific antibody has entered the market, their robust pipeline suggests that several bispecific antibodies will gain entry into the market during the forecast period, thus boosting this segment.
As per our report findings, the global leukemia antibody therapeutics market is expected to surpass US$ 4 Billion by 2028. Several factors are boosting the growth of market including increasing burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. Moreover, large number of investments made in this segment has enabled pharmaceutical companies to develop more enhanced antibody therapeutics for the management of leukemia. Many pharmaceutical giants are also focusing on developing novel next generation antibody products for the treatment of leukemia in order to maintain their competitive advantage and penetrate new regional markets.
Global Leukemia Cancer Antibodies Market, Drug Sales and Clinical Trials Insight 2028 Report Highlights:
- Leukemia Cancer Antibodies Market Global and Regional Outlook
- Global Leukemia Cancer Antibodies Market Opportunity > USD 4 Billion
- Global and Regional Sales Analysis
- Leukemia Cancer Antibody Drug Conjugates, Monoclonal Antibodies, Bispecific Antibodies Insight
- Pricing, Dosage, Patent Insight On Approved Leukemia Cancer Antibodies
- Comprehensive Insight On More Than 100 Leukemia Cancer Antibodies in Clinical Trials
- Leukemia Cancer Antibodies in Clinical Trials Insight By Phase, Company, Orphan Designation
The genomic analysis has demonstrated high expression of CD20 and CD33 on the leukemic cells. Therefore, these receptors have emerged as promising druggable targets for the immunotherapeutic approaches. At present, a cocktail of monoclonal antibodies and antibody drug conjugates directed towards these receptors have entered the global market. Moreover, bispecific antibody targeting CD19 as well as CD3 has also been approved for the management of acute lymphoblastic leukemia. The encouraging response of this therapeutics has propelled the further research and development activities in this domain. Presently, more than 100 clinical trials are ongoing in global leukemia antibody therapeutics market.
US is currently holding the maximum number of clinical trials in the market which is mainly attributed to the presence of major key players in the region associated with their huge investments in this segment. For instance, Immunogen has developed IMGN632, which is a CD123 targeted antibody drug conjugate in clinical development for the management of acute myeloid leukemia. Researchers are evaluating the role of investigational drug in combination with Vidaza (azacitidine) and Venclexta® (venetoclax) (triplet) in patients with relapsed/ refractory (R/R) acute myeloid leukemia. The drug is present in initial stages of development and is expected to gain entry in market during the forecast period.
Apart from US, China is also making huge investments in antibody therapeutics to cope up with the market growth. The China pharmaceutical market is also expanding at large rates owing to presence of both domestic as well as international players. The growth is reliant on supportive government policies, favorable healthcare coverage rates, advancements in medical technology, and new product launches in the market. In 2020, National Medical Products Administration (NMPA) of China has announced the approval of Halpryza (rituximab injection). In addition, other key growth drivers for the market in China include the ageing trend of Chinese population, rising healthcare expenditure, and improving the public medical insurance system.
At present, therapeutic monoclonal antibodies are currently dominating the global market which is mainly attributed to large number of product approved, availability of cost effective biosimilars, and favorable reimbursement policies. However, it is estimated that bispecific antibodies will emerge as potential therapeutic option in the management of leukemia owing to their enhanced efficacy and specificity in the management of disease. Although only one bispecific antibody has entered the market, their robust pipeline suggests that several bispecific antibodies will gain entry into the market during the forecast period, thus boosting this segment.
As per our report findings, the global leukemia antibody therapeutics market is expected to surpass US$ 4 Billion by 2028. Several factors are boosting the growth of market including increasing burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. Moreover, large number of investments made in this segment has enabled pharmaceutical companies to develop more enhanced antibody therapeutics for the management of leukemia. Many pharmaceutical giants are also focusing on developing novel next generation antibody products for the treatment of leukemia in order to maintain their competitive advantage and penetrate new regional markets.
1. RESEARCH METHODOLOGY
2. GLOBAL LEUKEMIA ANTIBODY MARKET OVERVIEW
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity
3. GLOBAL LEUKEMIA ANTIBODIES CLINICAL TRIALS OVERVIEW
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Patient Segment
4. LEUKEMIA ANTIBODY DRUG CONJUGATES INSIGHT
4.1 Overview
4.2 Drugs Availability, Patent, Price & Dosage Analysis
5. LEUKEMIA MONOCLONAL ANTIBODY INSIGHT
5.1 Overview
5.2 Drugs Availability, Patent, Price & Dosage Analysis
6. LEUKEMIA BISPECIFIC ANTIBODY INSIGHT
6.1 Overview
6.2 Drugs Availability, Patent, Price & Dosage Analysis
7. GLOBAL LEUKEMIA ANTIBODIES – GLOBAL & REGIONAL SALES ANALYSIS
7.1 Besponsa
7.2 Rituxan
7.3 Gazyva
7.4 Blincyto
8. GLOBAL LEUKAEMIA ANTIBODIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
8.7 Preregistration
8.8 Registered
9. MARKETED LEUKAEMIA ANTIBODIES CLINICAL, PATENT & ORPHAN DESIGNATION INSIGHT
10. COMPETITIVE LANDSCAPE
10.1 Amgen
10.2 Amphivena Therapeutics
10.3 AstraZeneca
10.4 Eli Lilly
10.5 GlaxoSmithKline
10.6 Innovent
10.7 Janssen Pharmaceuticals
10.8 Jasper Therapeutics
10.9 Pfizer
10.10 Roche
2. GLOBAL LEUKEMIA ANTIBODY MARKET OVERVIEW
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity
3. GLOBAL LEUKEMIA ANTIBODIES CLINICAL TRIALS OVERVIEW
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Patient Segment
4. LEUKEMIA ANTIBODY DRUG CONJUGATES INSIGHT
4.1 Overview
4.2 Drugs Availability, Patent, Price & Dosage Analysis
5. LEUKEMIA MONOCLONAL ANTIBODY INSIGHT
5.1 Overview
5.2 Drugs Availability, Patent, Price & Dosage Analysis
6. LEUKEMIA BISPECIFIC ANTIBODY INSIGHT
6.1 Overview
6.2 Drugs Availability, Patent, Price & Dosage Analysis
7. GLOBAL LEUKEMIA ANTIBODIES – GLOBAL & REGIONAL SALES ANALYSIS
7.1 Besponsa
7.2 Rituxan
7.3 Gazyva
7.4 Blincyto
8. GLOBAL LEUKAEMIA ANTIBODIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
8.7 Preregistration
8.8 Registered
9. MARKETED LEUKAEMIA ANTIBODIES CLINICAL, PATENT & ORPHAN DESIGNATION INSIGHT
10. COMPETITIVE LANDSCAPE
10.1 Amgen
10.2 Amphivena Therapeutics
10.3 AstraZeneca
10.4 Eli Lilly
10.5 GlaxoSmithKline
10.6 Innovent
10.7 Janssen Pharmaceuticals
10.8 Jasper Therapeutics
10.9 Pfizer
10.10 Roche
LIST OF FIGURES
Figure 2-1: Global – Leukemia Incidences & Deaths, 2020 & 2030
Figure 2-2: Global – Leukemia Antibodies Therapeutics Market Size (US$ Billion), 2018 - 2021
Figure 2-3: Global – Leukemia Antibodies Therapeutics Market Size by Type (US$ Million), 2021
Figure 2-4: Global – Leukemia Antibodies Therapeutics Market Size by Type (%), 2021
Figure 2-5: Global – Leukemia Antibodies Therapeutics Market Size by Region (US$ Billion), 2021
Figure 2-6: Global – Leukemia Antibodies Therapeutics Market Size by Region (%), 2021
Figure 2-7: Global – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-8: US – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-9: Europe – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-10: China – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-11: Japan – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 3-1: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-2: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-3: Global - Leukemia Antibodies in Clinical Trials by Phase, 2022 till 2028
Figure 3-4: Global - Leukemia Antibodies in Clinical Trials by Patient Segment, 2022 till 2028
Figure 4-1: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year
Figure 4-2: Mylotarg – Approval Year by Region
Figure 4-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US$), May’2022
Figure 4-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 4-5: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 4-6: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), May’2022
Figure 4-7: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 4-8: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 4-9: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 4-10: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), May’2022
Figure 4-11: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, May’2022
Figure 4-12: Besponsa - Approval Year by Region
Figure 4-13: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US$), May’2022
Figure 4-14: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 4-15: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
Figure 4-16: Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
Figure 4-17: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), May’2022
Figure 4-18: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)
Figure 4-19: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 4-20: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 4-21: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), May’2022
Figure 5-1: Rituxan – FDA Approval Year by Indication
Figure 5-2: MabThera – Approval Year by Region
Figure 5-3: US– Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 5-4: US – Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 5-5: US – Price for a Supply of 100 ml & Price Per ml of Solution Rituxan for Injection (US$), May’2022
Figure 5-6: UK - Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 5-7: UK - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 5-8: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-9: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), May’2022
Figure 5-10: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), May’2022
Figure 5-11: UK – Cost of 50ml Truxima 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-12: UK – Cost of 2 Vials of Truxima 100mg/10ml Solution & Per Unit Cost of Vial (GBP/US$), May’2022
Figure 5-13: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-14: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-15: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-16: Riabni – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-17: Ruxience – Approval Year by Region
Figure 5-18: US – Cost of Supply of 10ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 5-19: US – Cost of Supply of 50ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 5-20: UK – Cost of 50ml Ruxience 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-21: UK – Cost of 10ml Ruxience 100mg/10ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-22: Riabni – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-23: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), May’2022
Figure 5-24: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), May’2022
Figure 5-25: Rituxan Hycela – Duration of CLL Treatment (Weeks)
Figure 5-26: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), May’2022
Figure 5-27: Gazyva – Approval Year by Cancer Type
Figure 5-28: Gazyva – Price for 40ml Supply & Price Per ml of Intravenous Solution (US$), May’2022
Figure 5-29: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg)
Figure 5-30: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week)
Figure 5-31: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), February’2022
Figure 5-32: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), May’2022
Figure 5-33: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US$), May’2022
Figure 5-34: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg)
Figure 5-35: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks)
Figure 5-36: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), May’2022
Figure 5-37: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg)
Figure 5-38: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), May’2022
Figure 5-39: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg)
Figure 5-40: Arzerra – Treatment Duration for Refractory CLL (Weeks)
Figure 5-41: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), May’2022
Figure 6-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL
Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days)
Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), May’2022
Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), February’2022
Figure 7-1: Besponsa – Quarter 1 Sales by Region (US$ Million), 2022
Figure 7-2: Besponsa – Quarter 1 Sales by Region (%), 2022
Figure 7-3: Global - Besponsa Annual Sales (US$ Million), 2020 & 2021
Figure 7-4: Global - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-5: US - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-6: Europe - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-7: ROW - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-8: Besponsa - Annual Sales by Region (US$ Million), 2020 & 2021
Figure 7-9: Besponsa - Quarterly Sales by Region (%), 2020
Figure 7-10: Besponsa - Quarterly Sales by Region (%), 2021
Figure 7-11: Rituxan – Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 7-12: Global - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-13: US - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-14: Europe - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-15: Japan - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-16: ROW - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-17: Rituxan - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 7-18: Rituxan - Annual Sales Value by Region (%), 2021
Figure 7-19: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 7-20: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 7-21: Gazyva – Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 7-22: Global - Gazyva Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-23: US - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-24: Europe - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-25: Japan - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-26: ROW - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-27: Gazyva - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 7-28: Gazyva - Annual Sales Value by Region (%), 2021
Figure 7-29: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
Figure 7-30: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-31: Blincyto – Quarter 1 Sales by Region (US$ Million), 2022
Figure 7-32: Blincyto – Quarter 1 Sales by Region (%), 2022
Figure 7-33: Blincyto – Sales Value (US$ Million), 2018 - 2021
Figure 7-34: US – Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 7-35: ROW – Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 7-36: Global – Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-37: US – Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-38: ROW – Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-39: Blincyto – Annual Sales Value by Region (US$ Million), 2021
Figure 7-40: Blincyto - Annual Sales Value by Region (%), 2021
Figure 2-1: Global – Leukemia Incidences & Deaths, 2020 & 2030
Figure 2-2: Global – Leukemia Antibodies Therapeutics Market Size (US$ Billion), 2018 - 2021
Figure 2-3: Global – Leukemia Antibodies Therapeutics Market Size by Type (US$ Million), 2021
Figure 2-4: Global – Leukemia Antibodies Therapeutics Market Size by Type (%), 2021
Figure 2-5: Global – Leukemia Antibodies Therapeutics Market Size by Region (US$ Billion), 2021
Figure 2-6: Global – Leukemia Antibodies Therapeutics Market Size by Region (%), 2021
Figure 2-7: Global – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-8: US – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-9: Europe – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-10: China – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-11: Japan – Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 3-1: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-2: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-3: Global - Leukemia Antibodies in Clinical Trials by Phase, 2022 till 2028
Figure 3-4: Global - Leukemia Antibodies in Clinical Trials by Patient Segment, 2022 till 2028
Figure 4-1: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year
Figure 4-2: Mylotarg – Approval Year by Region
Figure 4-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US$), May’2022
Figure 4-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 4-5: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 4-6: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), May’2022
Figure 4-7: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 4-8: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 4-9: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 4-10: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), May’2022
Figure 4-11: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, May’2022
Figure 4-12: Besponsa - Approval Year by Region
Figure 4-13: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US$), May’2022
Figure 4-14: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 4-15: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
Figure 4-16: Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
Figure 4-17: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), May’2022
Figure 4-18: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)
Figure 4-19: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 4-20: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 4-21: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), May’2022
Figure 5-1: Rituxan – FDA Approval Year by Indication
Figure 5-2: MabThera – Approval Year by Region
Figure 5-3: US– Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 5-4: US – Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 5-5: US – Price for a Supply of 100 ml & Price Per ml of Solution Rituxan for Injection (US$), May’2022
Figure 5-6: UK - Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 5-7: UK - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 5-8: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-9: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), May’2022
Figure 5-10: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), May’2022
Figure 5-11: UK – Cost of 50ml Truxima 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-12: UK – Cost of 2 Vials of Truxima 100mg/10ml Solution & Per Unit Cost of Vial (GBP/US$), May’2022
Figure 5-13: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-14: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-15: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-16: Riabni – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-17: Ruxience – Approval Year by Region
Figure 5-18: US – Cost of Supply of 10ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 5-19: US – Cost of Supply of 50ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 5-20: UK – Cost of 50ml Ruxience 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-21: UK – Cost of 10ml Ruxience 100mg/10ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-22: Riabni – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-23: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), May’2022
Figure 5-24: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), May’2022
Figure 5-25: Rituxan Hycela – Duration of CLL Treatment (Weeks)
Figure 5-26: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), May’2022
Figure 5-27: Gazyva – Approval Year by Cancer Type
Figure 5-28: Gazyva – Price for 40ml Supply & Price Per ml of Intravenous Solution (US$), May’2022
Figure 5-29: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg)
Figure 5-30: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week)
Figure 5-31: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), February’2022
Figure 5-32: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), May’2022
Figure 5-33: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US$), May’2022
Figure 5-34: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg)
Figure 5-35: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks)
Figure 5-36: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), May’2022
Figure 5-37: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg)
Figure 5-38: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), May’2022
Figure 5-39: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg)
Figure 5-40: Arzerra – Treatment Duration for Refractory CLL (Weeks)
Figure 5-41: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), May’2022
Figure 6-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL
Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days)
Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), May’2022
Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), February’2022
Figure 7-1: Besponsa – Quarter 1 Sales by Region (US$ Million), 2022
Figure 7-2: Besponsa – Quarter 1 Sales by Region (%), 2022
Figure 7-3: Global - Besponsa Annual Sales (US$ Million), 2020 & 2021
Figure 7-4: Global - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-5: US - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-6: Europe - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-7: ROW - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-8: Besponsa - Annual Sales by Region (US$ Million), 2020 & 2021
Figure 7-9: Besponsa - Quarterly Sales by Region (%), 2020
Figure 7-10: Besponsa - Quarterly Sales by Region (%), 2021
Figure 7-11: Rituxan – Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 7-12: Global - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-13: US - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-14: Europe - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-15: Japan - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-16: ROW - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-17: Rituxan - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 7-18: Rituxan - Annual Sales Value by Region (%), 2021
Figure 7-19: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 7-20: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 7-21: Gazyva – Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 7-22: Global - Gazyva Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-23: US - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-24: Europe - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-25: Japan - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-26: ROW - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-27: Gazyva - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 7-28: Gazyva - Annual Sales Value by Region (%), 2021
Figure 7-29: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
Figure 7-30: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-31: Blincyto – Quarter 1 Sales by Region (US$ Million), 2022
Figure 7-32: Blincyto – Quarter 1 Sales by Region (%), 2022
Figure 7-33: Blincyto – Sales Value (US$ Million), 2018 - 2021
Figure 7-34: US – Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 7-35: ROW – Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 7-36: Global – Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-37: US – Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-38: ROW – Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-39: Blincyto – Annual Sales Value by Region (US$ Million), 2021
Figure 7-40: Blincyto - Annual Sales Value by Region (%), 2021
